1

2
Stephen Thomas Davis, Scott Howard Dickerson, Philip Anthony Harris, Robert Neil Hunter III, Lee Frederick Kuyper, Karen Elizabeth Lackey, Michael Joseph Luzzio, James Marvin Veal, Duncan Herrick Walker: Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors. SmithKline Beecham Corporation, John L Lemanowicz, April 9, 2002: US06369086 (39 worldwide citation)

The present invention relates generally to novel substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling pathways. In p ...


3
Stephen Thomas Davis, Scott Howard Dickerson, Stephen Vernon Frye, Philip Anthony Harris, Robert Neil Hunter III, Lee Frederick Kuyper, Karen Elizabeth Lackey, Michael Joseph Luzzio, James Marvin Veal, Duncan Herrick Walker: Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects. SmithKline Beecham Corporation, Jennifer L Fox, September 12, 2006: US07105529 (34 worldwide citation)

Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 alipha ...


4
Philip Anthony Harris, Lee Frederick Kuyper, Karen Elizabeth Lackey, James Marvin Veal: Substituted aza-oxindole derivatives. SmithKline Beecham Corporation, John L Lemanowicz, November 9, 2004: US06815439 (30 worldwide citation)

Substituted aza-oxindole derivatives useful as cyclin dependent kinase II inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e.g., alopecia, plantar-palmar syndrome, mucositis) induced by chemoptherapy and/or radiation therapy in a patient receiving such therap ...


5
Amogh Boloor, Mui Cheung, Ronda Davis, Philip Anthony Harris, Kevin Hinkle, Robert Anthony Mook Jr, Jeffery Alan Stafford, James Marvin Veal: Pyrimidineamines as angiogenesis modulators. SmithKline Beecham Corporation, Jennifer L Fox, September 12, 2006: US07105530 (23 worldwide citation)

Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also Includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.


6

7

8
Michael John Alberti, Ian Robert Baldwin, Mui Cheung, Stuart Cockerill, Stephen Flack, Philip Anthony Harris, David Kendall Jung, Gregory Peckham, Michael Robert Peel, Jennifer Gabriel Badiang, Kirk Stevens, James Marvin Veal: Fused pyrazole derivatives being protein kinase inhibitors. Glaxo Group, Lorie Ann Morgan, January 23, 2007: US07166597 (6 worldwide citation)

Compounds of Formula (I): salts or solvates or physiologically functional derivatives thereof, wherein Z is CH or N, and R1, R2, and R4 are various substituent groups, are protein kinase inhibitors


9
Amogh Boloor, Mui Cheung, Ronda Davis, Philip Anthony Harris, Kevin Hinkle, Robert Anthony Mook Jr, Jeffery Alan Stafford, James Marvin Veal: Pyrimidineamines as angiogenesis modulators. SmithKline Beecham Corporation, Jennifer L Fox, August 28, 2007: US07262203 (6 worldwide citation)

Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.


10
Philip Anthony Harris, Lee Frederick Kuyper, Karen Elizabeth Lackey, James Marvin Veal: Substituted aza-oxindole derivatives. SmithKline Beecham Corporation, John L Lemanowicz, September 23, 2003: US06624171 (6 worldwide citation)

Substituted aza-oxindole derivatives useful as cyclin dependent kinase 11 inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e.g., alopecia, plantar-palmar syndrome, mucositis) induced by chemoptherapy and/or radiation therapy in a patient receiving such therap ...